May 27, 2024
Global EYLEA Drug Market

Global EYLEA Drug Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Age-Related Macular Degeneration

The global EYLEA drug market is involved in treating eye diseases such as wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization. EYLEA, also known as Aflibercept injection, is prescribed for conditions in which abnormal blood vessels grow and leak fluid causing swelling in the macula, the part of the eye responsible for central vision. The drug helps in inhibiting vascular endothelial growth factor (VEGF) which is a protein that stimulates angiogenesis and vascular permeability.

The Global EYLEA Drug Market Size Is Estimated To Be Valued At US$ 8.79 Bn In 2024 And Is Expected To Exhibit A CAGR Of 7.2% Over The Forecast Period 2024-2031.

Key Takeaways

Key players operating in the global EYLEA drug market are Bayer, Regeneron Pharmaceuticals, Coherus Biosciences, Inc., And Klinge Biopharma. The key players are focusing on new product launches, expansions, acquisitions, and collaborations to gain a competitive advantage in the market. The increasing prevalence of age-related macular degeneration and other eye diseases across the world provides numerous opportunities for players in the EYLEA drug market. The global market players are expanding their presence in emerging markets like Asia Pacific and Latin America to tap the significant growth potential.

Market Drivers

The global EYLEA drug market is primarily driven by the rising geriatric population worldwide which is susceptible to age-related macular degeneration and diabetic retinopathy. As per estimates, approximately one-third of the world’s population is expected to be aged over 60 years by 2050. Furthermore, the increasing healthcare expenditure and improving access to diagnosis and treatment of eye diseases is also fueling the market growth.

Pest Analysis

Political: Government regulations for drug approval and pricing can impact sales and profits of Eylea. Changes in healthcare policies may positively or negatively impact growth.
Economic: Economic downturns can reduce disposable income and affect spending on Eylea treatment which is not completely covered by insurance. On the other hand, economic growth supports higher drug spending.
Social: Growing aging population and increasing prevalence of eye diseases like AMD and DR drives the demand for Eylea treatment. However, social stigma and lack of awareness in developing nations are challenges.
Technological: Advancements in drug delivery methods and combination therapies increase efficacy and convenience of treatment with Eylea. Wider acceptance of technology and digitization can facilitate access in remote areas. Focus on newer drug formulations also expands treatment options.

The regions accounting for major value share in the global Eylea drug market are North America and Europe due to presence of developed healthcare systems and high awareness levels among population and doctors. Key factors favouring high market value in these regions are early availability of drugs, favourable reimbursement policies, large aging population base and higher healthcare spending. The Asia Pacific region is identified as the fastest growing market driven by factors like large patient pools, increasing healthcare expenditure, expanding medical insurance coverage and growing penetration of cutting-edge treatment options especially in emerging economies.

Around half the population resides in developing countries with insufficient access to advanced eye care. However, enhanced focus on expanding healthcare access in rural areas, partnerships for generic drug supply and efforts to strengthen medical infrastructure can potentially make significant contribution to global market value from regions like Asia Pacific, Latin America, Middle East and Africa in the long run.

What are the key data covered in this Global EYLEA Drug Market report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Global EYLEA Drug Market’s growth between 2024 and 2031.

:- Accurate calculation of the size of the Global EYLEA Drug Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behavior

:- Global EYLEA Drug Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Global EYLEA Drug Market vendors

FAQ’s

Q.1 What are the main factors influencing the Global EYLEA Drug market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global EYLEA Drug Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global EYLEA Drug market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:

  1. Source: CoherentMI, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it